Wadhwa brings over two decades of experience driving growth, transformation, and customer-centric strategies in the medical devices and diagnostics sector
Routine regulatory filing confirms completion of demat and share transfer compliances for March quarter
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Piramal Pharma plans to offer fully paid-up equity shares through a rights issue to its existing eligible shareholders
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
The company is one of the most profitable companies manufacturing speciality chemicals in India
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
The companies plan to use the proceeds to retire debt and expand operations
Subscribe To Our Newsletter & Stay Updated
